In early December, a Philadelphia state court ruled against the makers of the anticoagulant Xarelto, ordering them to pay $27.8 million in damages due to their failure to warn patients and the medical community about the drug’s potential to cause internal bleeding. Drug makers Bayer AG and Johnson & Johnson... Read more »

A phase III clinical study exploring the use of Xarelto (rivaroxaban) in preventing strokes and embolism in recent stroke patients has been stopped because Xarelto showed no more efficacy than the current recommended care, low doses of aspirin, while also demonstrating higher bleeding rates than aspirin. Study “Stopping Early for... Read more »

The blood thinner Xarelto and other anticoagulants caused more than 3,000 deaths in 2016, according to a recent report by the Institute for Safe Medication Practices (ISMP). Its QuarterWatch indicates that nearly 22,000 adverse event reports were sent to the FDA last year about anticoagulants such as Xarelto, Pradaxa, Eliquis,... Read more »

A review of adverse event reporting to the FDA in 2015 conducted by the Institute for Safe Medication Practices (ISMP) has revealed that Xarelto (rivaroaban) and its side effects were connected to more cases of serious harm than any other drug included in the survey. The next-generation anticoagulant drug came... Read more »

Xarelto, a highly touted alternative to the blood-thinning medication Warfarin, has come under fire with questions about the clinical trial that led to its approval. Faulty equipment used to monitor some of the patients in the trial may have contributed to results that made Xarelto look superior to warfarin, leading... Read more »

The Xarelto multidistrict litigation in Louisiana continues to grow, as another lawsuit was added to the ongoing proceedings on February 11. Estella Roethler filed a lawsuit individually and as the representative of the estate of Augustina Asocar Rodriguez. Rodriguez was prescribed and ingested the blood thinning medication from approximately January... Read more »

According to recently-released research findings, next-generation blood-thinning drug Xarelto may pose additional risk to patients who are already suffering from kidney disease. The study, based on data taken from the Department of Defense electronic medical records system, found that those with existing kidney ailments were significantly more likely to experience... Read more »

The presiding judge in the coordinated Xarelto lawsuit proceedings has issued a case management order stipulating the injury categories into which cases must be grouped to be considered for potential bellwether trials, which are expected to take place in 2017 as part of the multidistrict litigation (MDL 2592) created to manage... Read more »

Thousands of Xarelto users have brought federal lawsuits against the drug’s manufacturers alleging that the anticoagulant caused uncontrollable bleeding and severe injuries. Recent reports shed light on a how the drug made it to the market with FDA approval. The anticoagulant’s drug trial was based on what may have been a... Read more »

On December 2, 2015, six additional claimants added their causes of action to the pending multidistrict litigation (MDL) involving the blood-thinning drug Xarelto. Xarelto, which is also known rivaroxaban, is a relatively new blood thinning drug touted to offer patients an increased level of convenience as they treat their underlying... Read more »